Overview |
bs-10396R |
OPRD1 Polyclonal Antibody |
WB, ELISA, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
This antibody may also have a weak secondary cross-reaction with Mu-type opioid receptor, which is primarily expressed in the adrenal gland and testis. This is predicted based upon a 79% non-contiguous sequence similarity. |
Human, Mouse, Rat |
Dog, Cow, Pig, Chicken, Rabbit, Guinea Pig |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human OPRD1 |
81-180/372 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
4985 |
P41143 |
Cell membrane |
OPRD; Delta-type opioid receptor; D-OR-1; DOR-1; OPRD1 |
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |